Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY<\/b><\/p>\n
SHANGHAI<\/span>, March 26, 2025 \/PRNewswire\/ — On March 25, 2025<\/span>, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”or “the Group”; Stock Code: 600196.SH, 02196.HK),<\/b> a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended 31 December 2024<\/span> (“the Reporting Period”).<\/span><\/p>\n In 2024, Fosun Pharma further focused on the business development of innovative drugs and high-value devices, achieving operating revenue of RMB41.07 billion<\/span> and net profit attributable to shareholders of RMB2.77 billion<\/span>, representing an increase of 16.08% YoY. Fosun Pharma continuously optimize supply chain management to enhance operational efficiency, recording an operating cash flow of RMB4.48 billion<\/span> with an increase of 31.13% YoY, surpassing the growth rate of operating profit.<\/b> In addition, Fosun Pharma continues to advance lean management across quality enhancement, cost control, efficiency improvement, cycle management, and innovation R&D, driving operational efficiency and expanding profitability. During the Reporting Period, the gross margin minus the selling and distribution expense ratio improved by 2.45 percentage points YoY; and, excluding the impact of newly acquired enterprises during the Reporting Period and the same period last year, administrative expenses declined by RMB355 million<\/span>.<\/p>\n Fosun Pharma always takes innovation as a core driving force in its development. Fosun Pharma has established an open and globally integrated pharmaceutical R&D ecosystem, focusing on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody\/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powered drug discovery.<\/p>\n During the Reporting Period, Fosun Pharma continuously optimized its innovative R&D system while maintaining stable R&D investment, focusing on key pipeline strengths and enhancing efficiency through system integration. In 2024, Fosun Pharma’s total R&D expenditure amounted to RMB5.55 billion<\/span>, with R&D expenses totaling RMB3.64 billion<\/span>. The R&D expenditure in the pharmaceutical manufacturing segment amounted to RMB4.91 billion<\/span>, accounting for 16.98% of pharmaceutical business revenue.<\/b> There are over 80 major pipeline projects on innovative drugs and biosimilars (calculated by indications). In addition, during the Reporting Period, the pharmaceutical manufacturing segment of Fosun Pharma submitted 220 patent applications, including 3 American patent applications, 18 PCT applications, and Fosun Pharma has obtained 66 licensed invention patents authorization.<\/p>\n Accelerating Innovation Transformation and the Internationalization of Innovative Products<\/b><\/p>\n Focusing on unmet clinical needs, Fosun Pharma continuous to push forward its innovation transformation and the development and commercialization of innovative products, expanding into regulatory markets such as the U.S. and the EU.<\/b> During the Reporting Period, 7 innovative products\/biosimilars with a total of 16 indications independently developed and licensed-in by Fosun Pharma were approved for launch, and 8 innovative products\/biosimilars had entered the pre-launch approval\/critical clinical stage. Fosun Pharma also had 18 innovative products\/biosimilar projects (calculated by indications) initiated clinical trials.<\/p>\n In the field of lung cancer, Fosun Pharma has developed a comprehensive layout in innovative drugs and precision diagnostics and treatment to benefit patients globally.<\/b> Fosun Pharma’s self-developed innovative anti-PD-1 monoclonal antibody, Han Si Zhuang<\/span> (Serplulimab Injection), is the world’s first anti-PD-1 monoclonal antibody (mAb) approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), and it remains the first and only anti-PD-1 mAb approved in the EU for the treatment of ES-SCLC. During the Reporting Period, Han Si Zhuang<\/span> also received approval in Chinese mainland for the treatment of non-squamous non-small cell lung cancer (nsNSCLC), and this also marked its third indication in the field of lung cancer, further expanding its reach. To date, Han Si Zhuang<\/span> has been approved for marketing in over 30 countries and regions, including China<\/span>, the European Union, and several Southeast Asian nations, benefiting more than 100,000 patients.<\/b> In addition, to help more lung cancer patients obtain early diagnosis and treatment in a more minimally invasive way, the Ion Bronchial Navigation Operation Control System (Ion System) of Intuitive Fosun, Fosun Pharma’s associated company, received NMPA approval in March 2024<\/span> and has been commercially deployed.<\/p>\n In high-incidence cancers such as breast and gastric cancers,<\/b> Fosun Pharma’s self-developed monoclonal antibody(mAb) biosimilar Han Qu You<\/span> (Trastuzumab Injection) has been approved for launch in over 50 countries and regions, including China<\/span>, the European Union, the U.S., Canada<\/span> and Australia<\/span>, and has been included in the health insurance directories in countries such as China<\/span>, UK, France<\/span>, and Germany<\/span>. To date, Han Qu You<\/span> has benefited over 240,000 patients. The HER2-targeted innovative monoclonal antibody HLX22 for gastric cancer treatment and the novel endocrine therapy HLX78 (lasofoxifene) for breast cancer are currently under international multi-center Phase III clinical trials. Additionally, the biosimilar candidate HLX11 (pertuzumab) has had its new drug applications submitted and accepted in both China<\/span> and the U.S., injecting new momentum into global expansion.<\/p>\n In addition, Fosun Pharma is also advancing the development of rare disease drugs.<\/b> Its self-developed MEK1\/2 selective inhibitor Luvometinib tablets, (Project Code: FCN-159), has had its new drug applications for two indications\u2014treatment of adult dendritic cell and histiocytic tumors, and treatment of plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1) in children aged 2 years and older\u2014accepted by the NMPA and placed in the priority review process. In the non-oncology field,<\/b> during the Reporting Period, Fosun Pharma’s self-developed and licensed-in rabies vaccine (Vero cell) for human use (freeze dried), Pu Rui Ni (Pretomanid Tablets), Han Da Yuan<\/span> (Adalimumab Injection) received approval for four new indications, and Su ke Xin (Avatrombopag Malate Tablets) was approved for its second indication in China<\/span>; meanwhile, the new drug applications for a biosimilar of denosumab HLX14 under development were accepted by the European Medicines Agency (EMA), Health Canada and the FDA, respectively.<\/p>\n Continuously Enhancing Global Operations and Bilateral Licensing Cooperation<\/b><\/p>\n Fosun Pharma continues to uphold the internationalization strategy in multiple dimensions, such as innovative R&D, licensing, manufacturing and operations as well as commercialization<\/b>. In 2024, overseas revenue reached RMB11.30 billion<\/span>, accounting for 27.51% of total revenue.<\/p>\n During the reporting period, Fosun Pharma continues to promote the building of production system with international quality standard, laying a solid foundation for the overseas distribution of preparations. As of the end of 2024, all production lines of the domestic subsidiaries under the pharmaceutical manufacturing segment of Fosun Pharma obtained domestic GMP certifications and 10 production lines had passed GMP certification in major regulatory markets such as the U.S. and the EU.<\/p>\n Fosun Pharma’s pharmaceuticals and medical devices businesses now primarily cover major overseas markets, including the United States<\/span>, Europe<\/span>, Africa<\/span>, India<\/span>, and Southeast Asia<\/span>, with an overseas commercialization team of over 1,000 employees. In the U.S., Fosun Pharma’s in-house generic drug team has continued to grow, establishing partnerships with major distributors and group purchasing organizations (GPOs) to drive the sales of formulation products. Meanwhile, Fosun Pharma has established its innovative drug team in the U.S. and is preparing for the commercialization of its anti-PD-1 monoclonal antibody (mAb), serplulimab injection.<\/p>\n In Europe<\/span>, Gland Pharma has built localized manufacturing capabilities through its subsidiary, Cenexi. Sisram Medical has expanded its global direct sales offices to 12, with its marketing network now covering over 110 countries and regions. The share of direct sales revenue has further increased to 87%. Meanwhile, Breas Medical’s marketing network has expanded across key mature markets, including Europe<\/span>, the United States<\/span>, Japan<\/span>, and Australia<\/span>.<\/p>\n In emerging markets, Fosun Pharma’s sales network in Africa<\/span> now covers over 40 countries and regions. The company continues to advance the C\u00f4te d’Ivoire park project to establish localized pharmaceutical manufacturing and supply in Africa<\/span>. In February 2025<\/span>, Fosun Pharma launched a new pharmaceutical and medical device sales platform in Nanning, gradually enhancing its registration and commercialization capabilities in Southeast Asia<\/span> to expand its presence in the region.<\/p>\n Fosun Pharma is also actively expanding into the Middle East<\/span> market. During the reporting period, Henlius, a subsidiary of Fosun Pharma, entered into a strategic partnership with SVAX to establish a joint venture in Saudi Arabia<\/span>. This collaboration aims to enhance the accessibility of innovative and high-value products in the MENAT region (Middle East<\/span>, North Africa<\/span>, and Turkey<\/span>).<\/p>\n Fosun Pharma continues to strengthen its global licensing collaboration, further enhancing its international influence and competitiveness. On the out-licensing front, Henlius, a subsidiary of Fosun Pharma has forged deep partnerships with over 20 leading global biopharmaceutical companies, including Accord, Abbott, Eurofarma, KGbio, Organon, and Dr. Reddy’s, to jointly expand global markets. These collaborations comprehensively cover major biologics markets in Europe<\/span> and the U.S., as well as numerous emerging markets. To date, its approved biologics have benefited more than 750,000 patients worldwide.<\/p>\n Fosun Pharma continues to expand its product pipeline in core therapeutic areas through strategic global collaborations. Licensed-in products such as the antiemetic Akynzeo\u00ae (netupitant\/palonosetron capsules), long-lasting recombinant human granulocyte colony-stimulating factor product (Pei Jin<\/span>) and the drug for heart failure and hypertension treatment (Yi Xin Tan<\/span>) have been included in the National Medical Insurance Drugs Catalogue, benefiting a wide range of patients. Fosun Pharma has obtained exclusive development and commercialization rights for Tenapanor Hydrochloride Tablets (Wan Ti Le), a first-in-class phosphate-lowering drug with a novel mechanism. In February 2025<\/span>, the drug received approval from the National Medical Products Administration (NMPA) in China<\/span> for the treatment of hyperphosphatemia in adult dialysis patients with chronic kidney disease (CKD). This approval marks a new era of multi-mechanism phosphate control, bringing new hope to dialysis patients with hyperphosphatemia. During the reporting period, Fosun Pharma’s licensed product Daxxify\u00ae (DaxibotulinumtoxinA-lanm) became the first of its kind approved in China<\/span>. The product received NMPA approval for the improvement in the appearance of moderate to severe glabellar lines associated with corrugator and\/or procerus muscle activity in adult patients.<\/p>\n Accelerating Localization of Innovative Products in China<\/span> to Achieve High-quality Development<\/b><\/p>\n As a global innovation-driven pharmaceutical and healthcare company, Fosun Pharma actively introduces internationally advanced technologies and products to the Chinese market, benefiting patients and customers.<\/b> During the reporting period, Fosun-Insightec, a joint venture established with Insightec in China<\/span>, successfully achieved sales of magneticresonance image guided focused ultrasound brain therapy system (“MRgFUS brain therapy system”) for brain treatment. Additionally, the headquarters and industrial base of Intuitive Fosun, an associated company, was officially inaugurated in the Zhangjiang International Medical Park in Shanghai<\/span>. This facility integrates R&D, manufacturing, and training, further accelerating the localization of the da Vinci Robotic surgical systems in China<\/span>.<\/p>\n To further enhance its leading position in tumor immunotherapy, Fosun Pharma increased its stake in its cell therapy platform, Fosun Kairos, to 100% during the reporting period. The company will continue to collaborate with Kite Pharma to advance the development and commercialization of its licensed products, Axi-Cel (marketed as Yi Kai Da ) and Brexu-Cel (investigational project FKC889), in Chinese mainland, Hong Kong S.A.R and Macao S.A.R. Yi Kai Da became the first in China<\/span> to introduce an innovative outcome-based payment model. As of the end of 2024, Yi Kai Da has benefited over 800 lymphoma patients, been included in more than 110 provincial and municipal government-backed insurance programs and over 80 commercial insurance plans, and has been registered in more than 180 treatment centers across 28 provinces and municipalities nationwide.<\/p>\n While maintaining steady operations, Fosun Pharma remains committed to its corporate social responsibilities. In 2024, the company received multiple domestic and international accolades for its significant progress in ESG, including recognition as one of China’s<\/span> ESG Listed Company Pioneer 100, Deloitte’s China Best Managed Companies, Charity Star<\/span>, and Forbes 2024 China ESG 50 list. Additionally, Fosun Pharma’s MSCI ESG rating remained at A.<\/p>\n “Fosun Pharma will continue to adhere to innovation-driven and global development strategies, actively embrace AI, concentrate resources on core businesses, and persistently advance lean management and enhance operational efficiency.” Wu Yifang, Chairman of Fosun Pharma<\/b> said, “We aim to grow in tandem with China’s<\/span> biopharmaceutical industry and stride into a new phase of high-quality development. Upholding our mission to ‘create better health for families worldwide’, we will maintain a patient-centric approach, address unmet clinical needs, deepen innovation transformation and global expansion, and strive to become a global leader in healthcare innovation and integration.”<\/p>\n Ab<\/span>out Fosun Pharma<\/b><\/p>\n Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; SSE: 600196, HKEX: 02196) is a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with Sinopharm Group Co., Ltd., Fosun Pharma further extends its capabilities in pharmaceutical commerce.<\/p>\n Over the past 30 years since its establishment, Fosun Pharma has maintained deep roots in China<\/span> while strategically expanding its global presence. The company has been actively implementing its “4IN” strategy -Innovation, Internationalization, Intelligentization, and Integration, with core business operations now spanning major overseas markets including the United States<\/span>, Europe<\/span>, Africa<\/span>, India<\/span>, and Southeast Asia<\/span>. At present, Fosun Pharma has established an open and globally integrated pharmaceutical R&D ecosystem, focusing on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody\/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powered drug discovery. This multidimensional approach accelerates the translation of innovative therapies into clinical practice, systematically addressing critical unmet medical needs worldwide.<\/p>\n Looking ahead, Fosun Pharma remains anchored in its core values of “Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership”. By advancing its global innovation engine and operational excellence, the company strives to be a global leader to integrate pharmaceutical and healthcare innovations, creating better health for families worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":" Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 26, 2025 \/PRNewswire\/ — On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”or “the Group”; Stock Code: 600196.SH, 02196.HK), a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended 31 December […]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-35046","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"\n